2 small cap ASX healthcare shares to watch

Could these ASX small cap healthcare shares follow in the footsteps of CSL Limited (ASX:CSL)?
The post 2 small cap ASX healthcare shares to watch appeared first on The Motley Fool Australia. –

Doctor pressing digitised screen with array of icons including one entitled health insurance

The Australian share market is home to a number of world class healthcare companies with long, proud histories like CSL Limited (ASX: CSL).

In addition to this, it is home to a number of exciting healthcare companies that are just beginning to write their stories.

While there certainly is still a lot of work to do, two that have been tipped for big things are listed below. Here’s what you need to know about them:

Mach7 Technologies Ltd (ASX: M7T)

The first small cap healthcare share to look at is Mach7. It is a medical imaging data management solutions provider which uses software to create a clear and complete view of the patient. This helps inform diagnosis, reduce care delivery delays and costs, and ultimately improves patient outcomes. The company has also expanded its offering this year with the acquisition of Client Outlook. It is a leading provider of an enterprise image viewing technology. This acquisition increases Mach7’s total addressable market from US$0.75 billion to US$2.75 billion.

Analysts at Morgans are very positive on the company’s prospects and have been pleased with the acquisition and integration of Client Outlook. Morgans notes that the company’s solutions are well-placed in the current environment where demand for telehealth is growing fast. The broker has an add rating and $1.49 price target on the company’s shares.

Volpara Health Technologies Ltd (ASX: VHT)

Volpara Health Technologies is a growing healthcare technology company that offers cost-effective, mission-critical software that help radiologists deliver the highest-quality breast imaging services. Volpara’s software uses artificial intelligence imaging algorithms to assist with the early detection of breast cancer. According to management, the company currently has a US$750 million annual recurring revenue (ARR) opportunity in breast cancer screening. This compares to the ARR of NZ$19.9 million it recorded in the first half of FY 2021.

Morgans is also positive on Volpara. It has an add rating and $1.71 price target on the company’s shares. The broker has been pleased with its market share gains, growing SaaS revenue, and high gross margins.

Where to invest $1,000 right now

When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

Scott just revealed what he believes are the five best ASX stocks for investors to buy right now. These stocks are trading at dirt-cheap prices and Scott thinks they are great buys right now.

See The 5 Stocks

*Returns as of June 30th

More reading

James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of and recommends CSL, MACH7 FPO and VOLPARA FPO NZ. The Motley Fool Australia has recommended MACH7 FPO and VOLPARA FPO NZ. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

The post 2 small cap ASX healthcare shares to watch appeared first on The Motley Fool Australia.

Trade The World Anywhere & Anytime!

Mobile app platform with over 50,000 global listed securities across 12 markets (over 70% global market capitalisation), right from your Android or iOS device.

Integrated with exclusive trading idea and investment analysis tools to help you find actionable insight on virtually every financial instrument across our 12 global markets, to help you optimise your trading strategies.

Refer Your Friends

Tell your friends about Monex and gift them FREE access to our trading tools.

We respect your privacy and will only send this one email notification to your friends. 

Share With Your Friends

Share on facebook
Share on twitter
Share on linkedin

Monex Trading Tools Access and Usage Terms

The Monex Trading Tools (referred to as ‘tools’ hereafter) are available to you inside your client portal;

To activate access to the tools, you must have a verified and approved trading account and have made a deposit of at least AUD $1000.

An active and funded account with a positive trading balance is required to continue to have access to the tools;

Although the tools are available to you indefinitely, Monex Securities may at it’s discretion disable access to the tools in the future;

Monex securities reserves the right to change these terms and conditions from time to time, as it sees fit, without notice.

Important Notice
iOS & Android App - 12 International Markets & Over 70% Global Market Cap. $0 Brokerage On US Trades. Click Here!